• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Alzheimer s Research & Therapy >Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment: a critical review
【24h】

Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment: a critical review

机译：药物和非药物治疗对阿尔茨海默氏病和轻度认知障碍脑功能磁共振成像的影响：一项重要综述

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brain changes after a short period of treatment. This critical review aimed to identify and discuss the available studies that have tested the efficacy of pharmacological and nonpharmacological treatments in AD and MCI cases using task-based or resting-state fMRI measures as primary outcomes. A PubMed-based literature search was performed with the use of the three macro-areas: ‘disease’, ‘type of MRI’, and ‘type of treatment’. Each contribution was individually reviewed according to the Cochrane Collaboration’s tool for assessing risk of bias. Study limitations were systematically detected and critically discussed. We selected 34 pharmacological and 13 nonpharmacological articles. According to the Cochrane Collaboration’s tool for assessing risk of bias, 40% of these studies were randomized but only a few described clearly the randomization procedure, 36% declared the blindness of participants and personnel, and only 21% reported the blindness of outcome assessment. In addition, 28% of the studies presented more than 20% drop-outs at short- and/or long-term assessments. Additional common shortcomings of the reviewed works were related to study design, patient selection, sample size, choice of outcome measures, management of drop-out cases, and fMRI methods. There is an urgent need to obtain efficient treatments for AD and MCI. fMRI is powerful enough to detect even subtle changes over a short period of treatment; however, the soundness of methods should be improved to enable meaningful data interpretation.
机译：已经进行了越来越多的药理和非药理试验，以测试批准的或实验性疗法在阿尔茨海默病（AD）和轻度认知障碍（MCI）中的功效。在这种情况下，功能性磁共振成像（fMRI）可能是在短期​​治疗后检测脑部变化的良好候选者。这项重要的评论旨在确定和讨论可用的研究，这些研究使用基于任务或静息状态的fMRI措施作为主要结果，测试了AD和MCI病例中药物和非药物治疗的有效性。基于PubMed的文献搜索使用了三个宏观区域：“疾病”，“ MRI类型”和“治疗类型”。每项贡献均根据Cochrane协作组织的评估偏见风险的工具进行了单独审核。研究局限性得到系统地检测和严格讨论。我们选择了34篇药理文章和13篇非药理文章。根据Cochrane Collaboration评估偏倚风险的工具，其中40％的研究是随机分组的，但只有少数明确描述了随机化程序，有36％的研究参与者和人员不知情，只有21％的研究报告了结果评估的盲目性。此外，在短期和/或长期评估中，有28％的研究表明辍学率超过20％。审查工作的其他常见缺陷与研究设计，患者选择，样本量，结局指标选择，辍学病例管理和fMRI方法有关。迫切需要获得针对AD和MCI的有效治疗方法。功能磁共振成像功能强大，足以在短时间内检测甚至细微的变化。但是，应该提高方法的可靠性，以实现有意义的数据解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号